Prostate Cancer Therapeutics Market Report

Prostate Cancer Therapeutics Market Analysis By Drugs (Zytiga, Gonax, Lupron, Zoladex, Decapeptyl, Eligard, Vantas, Casodex, Xtandi, Taxotere, Jevtana, Provenge, Xofigo), By Region, And Segment Forecasts, 2018 - 2025

  • Published Date: May 2017
  • Report ID: GVR-1-68038-925-8
  • Number of Pages: 90
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2015

Market Segmentation

  • Prostate Cancer Therapeutics Drug Class Outlook (Revenue, USD Billion; 2014 - 2025)
    • Hormonal Therapy
      • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • Zytiga
        • Gonax
      • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • Lupron
        • Zoladex
        • Eligard
        • Decapeptyl
        • Vantas
        • Others
      • Anti-Androgen
        • Xtandi
        • Casodex
    • Chemotherapy
      • Taxotere
      • Jevtana
    • Immunotherapy
      • Provenge
    • Targeted Therapy
      • Xofigo
  • Prostate Cancer Therapeutics Regional Outlook (Revenue, USD Billion; 2014 - 2025)
    • North America
      • U.S.
        • U.S. Prostate Cancer Therapeutics Drug Class Outlook (Revenue, USD Billion; 2014 - 2025)
          • Hormonal Therapy
            • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
              • Zytiga
              • Gonax
            • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
              • Lupron
              • Zoladex
              • Eligard
              • Decapeptyl
              • Vantas
              • Others
            • Anti-Androgen
              • Xtandi
              • Casodex
          • Chemotherapy
            • Taxotere
            • Jevtana
          • Immunotherapy
            • Provenge
          • Targeted Therapy
            • Xofigo
      • Canada
        • Canada Prostate Cancer Therapeutics Drug Class Outlook (Revenue, USD Billion; 2014 - 2025)
          • Hormonal Therapy
            • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
              • Zytiga
              • Gonax
            • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
              • Lupron
              • Zoladex
              • Eligard
              • Decapeptyl
              • Vantas
              • Others
            • Anti-Androgen
              • Xtandi
              • Casodex
          • Chemotherapy
            • Taxotere
            • Jevtana
          • Immunotherapy
            • Provenge
          • Targeted Therapy
            • Xofigo
    • Europe
      • Germany
        • Germany Prostate Cancer Therapeutics Drug Class Outlook (Revenue, USD Billion; 2014 - 2025)
          • Hormonal Therapy
            • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
              • Zytiga
              • Gonax
            • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
              • Lupron
              • Zoladex
              • Eligard
              • Decapeptyl
              • Vantas
              • Others
            • Anti-Androgen
              • Xtandi
              • Casodex
          • Chemotherapy
            • Taxotere
            • Jevtana
          • Immunotherapy
            • Provenge
          • Targeted Therapy
            • Xofigo
      • UK
        • UK Prostate Cancer Therapeutics Drug Class Outlook (Revenue, USD Billion; 2014 - 2025)
          • Hormonal Therapy
            • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
              • Zytiga
              • Gonax
            • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
              • Lupron
              • Zoladex
              • Eligard
              • Decapeptyl
              • Vantas
              • Others
            • Anti-Androgen
              • Xtandi
              • Casodex
          • Chemotherapy
            • Taxotere
            • Jevtana
          • Immunotherapy
            • Provenge
          • Targeted Therapy
            • Xofigo
    • Asia Pacific
      • China
        • China Prostate Cancer Therapeutics Drug Class Outlook (Revenue, USD Billion; 2014 - 2025)
          • Hormonal Therapy
            • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
              • Zytiga
              • Gonax
            • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
              • Lupron
              • Zoladex
              • Eligard
              • Decapeptyl
              • Vantas
              • Others
            • Anti-Androgen
              • Xtandi
              • Casodex
          • Chemotherapy
            • Taxotere
            • Jevtana
          • Immunotherapy
            • Provenge
          • Targeted Therapy
            • Xofigo
      • Japan
        • Japan Prostate Cancer Therapeutics Drug Class Outlook (Revenue, USD Billion; 2014 - 2025)
          • Hormonal Therapy
            • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
              • Zytiga
              • Gonax
            • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
              • Lupron
              • Zoladex
              • Eligard
              • Decapeptyl
              • Vantas
              • Others
            • Anti-Androgen
              • Xtandi
              • Casodex
          • Chemotherapy
            • Taxotere
            • Jevtana
          • Immunotherapy
            • Provenge
          • Targeted Therapy
            • Xofigo
    • Latin America
      • Mexico
        • Mexico Prostate Cancer Therapeutics Drug Class Outlook (Revenue, USD Billion; 2014 - 2025)
          • Hormonal Therapy
            • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
              • Zytiga
              • Gonax
            • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
              • Lupron
              • Zoladex
              • Eligard
              • Decapeptyl
              • Vantas
              • Others
            • Anti-Androgen
              • Xtandi
              • Casodex
          • Chemotherapy
            • Taxotere
            • Jevtana
          • Immunotherapy
            • Provenge
          • Targeted Therapy
            • Xofigo
      • Brazil
        • Brazil Prostate Cancer Therapeutics Drug Class Outlook (Revenue, USD Billion; 2014 - 2025)
          • Hormonal Therapy
            • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
              • Zytiga
              • Gonax
            • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
              • Lupron
              • Zoladex
              • Eligard
              • Decapeptyl
              • Vantas
              • Others
            • Anti-Androgen
              • Xtandi
              • Casodex
          • Chemotherapy
            • Taxotere
            • Jevtana
          • Immunotherapy
            • Provenge
          • Targeted Therapy
            • Xofigo
    • MEA
      • South Africa
        • South Africa Prostate Cancer Therapeutics Drug Class Outlook (Revenue, USD Billion; 2014 - 2025)
          • Hormonal Therapy
            • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
              • Zytiga
              • Gonax
            • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
              • Lupron
              • Zoladex
              • Eligard
              • Decapeptyl
              • Vantas
              • Others
            • Anti-Androgen
              • Xtandi
              • Casodex
          • Chemotherapy
            • Taxotere
            • Jevtana
          • Immunotherapy
            • Provenge
          • Targeted Therapy
            • Xofigo

Report content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2014 to 2025
  • Market estimates and forecast for product segments up to 2025
  • Regional market size and forecast for product segments up to 2025
  • Market estimates and forecast for application segments up to 2025
  • Regional market size and forecast for application segments up to 2025
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.